Not the Usual Suspects: Alternative Surfactants for Biopharmaceuticals

Therapeutically relevant proteins naturally adsorb to interfaces, causing aggregation which in turn potentially leads to numerous adverse consequences such as loss of activity or unwanted immunogenic reactions. Surfactants are ubiquitously used in biotherapeutics drug development to oppose interfacial stress, yet, the choice of the surfactant is extremely limited: to date, only polysorbates (PS20/80) and poloxamer 188 are used in commercial products. However, both surfactant families suffer from severe degradation and impurities of the raw material, which frequently increases the risk of particle generation, chemical protein degradation, and potential adverse immune reactions. Herein, we assessed a total of 40 suitable alternative surfactant candidates and subsequently performed a selection through a three-gate screening process employing four protein modalities encompassing six different formulations.

The screening is based on short-term agitation-induced aggregation studies coupled to particle analysis and surface tension characterization, followed by long-term quiescence stability studies connected to protein purity measurements and particle analysis. The study concludes by assessing the surfactant’s chemical and enzymatic degradation propensity. The candidates emerging from the screening are de novo α-tocopherol-derivatives named VEDG-2.2 and VEDS, produced ad hoc for this study. They display protein stabilization potential comparable or better than polysorbates together with an increased resistance to chemical and enzymatic degradation, thus representing valuable alternative surfactants for biotherapeutics.

Table S1. Details of all the surfactants investigated in this study.

IndexNameCategoryScreening drop out stagePubChem
SID
CAS No.MW
(Da)
HLBCMC
(w/v%)
1PS203N/A4724070079005-64-5122816.70.007
2PS803N/A4723859629005-65-6131015.00.002
3PLX1883N/A4724050589003-11-6840016.00.400
4Labrafil M2125 CS (Linoleoy Macrogol-6 glycerides)1113527895061789-25-1---
5Labrafil M1944 CS1147221711969071-70-1---
6Poly(ethylene glycol)
monooleate
124411527439004-96-086013.60.006
7Lansurf CDE-G1136390255168603-42-9---
8Lansurf CDE1136390255168603-42-9---
9Lansurf SMO 113638986601338-43-8---
10Lansurf STO85113638986539005-70-3---
11Lansurf STO1234111396426266-58-09571.8-
12Lansurf CAPO11
4841981368155-09-9---
13Suppocire a pellets1113535651385665-33-4---
14Gelucire 44/14 (Lauroyl
Macrogol-32 glycerides)
1144115333457107-95-6---
15Gelucire 48/16 pellets (Polyoxyl32 stereate)124411527449004-99-3622160.008
16Tefose 63 (PEG-6 stearate and
ethylene glycol palmitostearate
and PEG-32 stearate)
1144115274491031-31-1---
17Labrafil M 2130 CS (Lauroyl
Macrogol-6 Glyceride)
1144115333457107-95-6---
18Tefose 1500 (PEG-6
Stearate(and)PEG-32 Stearate)
114411527449004-99-3---
19Gelucire 50/13 Pellets (Stearoyl
Macrogol-32 Glyceride)
114724044999011-21-6---
20Gelucire 43/01 Pellets 1147074015985665-33-4---
21TCA Sodium Taurocholate
duretgul-M-007
11254774705345909-26-4---
22TCA Sodium Taurocholate 90%
duretgul-M3-013
11254774705345909-26-4---
23TCDCA
Taurochenodeoxycholate
GOSSEBR1-SSS011
11254774705345909-26-4---
24TCA Sodium Taurocholate 90%
duretgul-M3-003-006
11254774705345909-26-4---
25TCA Sodium Taurocholate11254774705345909-26-4---
26GLCA Glycolithocholic acid
GOSSEBR1-SSS015A
11375925049474-74-8---
27TCA Sodium Taurocholate 98%
duretgul-M3-01
11254774705345909-26-4---
28TDCA Taurodeoxycholic acid
M03-bigorf11-003
11363898662516-50-7---
29TLCA Taurolithocholic acid
M03-bigorf11-002
11363898662516-50-7---
30KoolAid Surfactant124342742982306441-11-0---
31Tallowamine polyethoxylated1238702172061791-26-215005.00.013
32Cholic glycine11341125635475-31-0---
33Kolliphor ELP1247066781961791-12-6250013.00.006
34SPGS 550M1332976780481125-67-9105710.70.002
35Brij30112547871169002-92-0---
36PQS-75012470636525521313-35-9158814.00.020
37PS-750-M (FI-750-M)124342145462135447-74-216.40.050
38VEDS24--165213.00.011
39VEDG-2.224--166612.90.040
40Brij58S24--144714.90.008

Download the supporting information here: Not the Usual Suspects: Alternative Surfactants for Biopharmaceuticals – Supporting Information

or read more

Sebastian Brosig, Stefano Cucuzza, Tim Serno, Karoline Bechtold-Peters, Jakob Buecheler, Matej Zivec, Oliver GermershausFabrice Gallou, Not the Usual Suspects: Alternative Surfactants for Biopharmaceuticals, ACS Appl. Mater. Interfaces, 2023
https://doi.org/10.1021/acsami.3c05610


Read more about “Surfactants” here:

Design of Redispersible High-Drug-Load Amorphous Formulations
Design of Redispersible High-Drug-Load Amorphous Formulations
You might also like